Related references
Note: Only part of the references are listed.A prospective real-world analysis of erenumab in refractory chronic migraine
Giorgio Lambru et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
Saad Kanaan et al.
CEPHALALGIA (2020)
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
Ashley Alex et al.
HEADACHE (2020)
Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine
Jennifer Robblee et al.
HEADACHE (2020)
No Wearing-Off Effect Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study
Andrew M. Blumenfeld et al.
HEADACHE (2020)
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study
Dawn C. Buse et al.
JOURNAL OF HEADACHE AND PAIN (2020)
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
Stephen D. Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Long-term safety, tolerability, and efficacy of fremanezumab in migraine A randomized study
Peter J. Goadsby et al.
NEUROLOGY (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study
Valentina Orlando et al.
BMJ OPEN (2020)
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
Richard B. Lipton et al.
HEADACHE (2020)
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
Hans-Christoph Diener et al.
NEUROLOGICAL RESEARCH AND PRACTICE (2020)
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
Hsiangkuo Yuan et al.
HEADACHE (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom
Pamela Vo et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Amy R. Tso et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)
Interictal burden attributable to episodic headache: findings from the Eurolight project
Christian Lampl et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Improving Medication Adherence in Migraine Treatment
Elizabeth K. Seng et al.
CURRENT PAIN AND HEADACHE REPORTS (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
The impact of headache in Europe: principal results of the Eurolight project
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2014)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Min Yang et al.
CEPHALALGIA (2011)
Current practice and future directions in the prevention and acute management of migraine
Peter J. Goadsby et al.
LANCET NEUROLOGY (2010)
Impact of headache in Europe: a review for the Eurolight project
Lars Jacob Stovner et al.
JOURNAL OF HEADACHE AND PAIN (2008)
A six-item short-form survey for measuring headache impact: The HIT-6 (TM)
M Kosinski et al.
QUALITY OF LIFE RESEARCH (2003)
Share Paper
